US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government agencies, private contractors and universities, leaving some of the nation’s ...

US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government ...

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Net Financial Debt: Decreased slightly compared ... Equity Ratio: Strengthened from 58% to 61%. Merck KGaA (MKGAF) achieved profitable growth across all three business sectors in Q1 2025, with ...

Revenue: €5.28b (up 3.1% from 1Q 2024). Net income: €735.0m (up 5.9% from 1Q 2024). Profit margin: 14% (in line with 1Q 2024). EPS: €1.69 (up from €1.60 in 1Q 2024). We've found 21 US ...

Revenue: €5.28b (up 3.1% from 1Q 2024). Net income: €735.0m (up 5.9% from 1Q 2024). Profit margin: 14% (in line with 1Q 2024). EPS: €1.69 (up from €1.60 in 1Q 2024). We've found 21 US stocks that are ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

In an interview with CNBC at this week's Davos World Economic Forum, Merck KGaA’s CEO Stefan Oschman said that he is “absolutely certain” that a pharma company ranked among the 50 largest in ...

Universal Display appears reasonably valued, and its prospects have improved after its recent blue OLED breakthrough. Read ...

Trump has claimed the move could cut US drug prices by 30 to 80 percent. However, according to German consultancy ...

Merck KGaA's recent stock dip of 13% might scream trouble, but under the hood, things look remarkably solid. Despite a ...